Avitia improves cancer treatment via advanced molecular testing solutions. Avitia offer testing tools for use on-site, bioinformatics driven by AI, and actionable insights aimed at enhancing patient outcomes. Avitia offerings comprise pre-prepared NGS panels, simplified reporting mechanisms, and cooperative diagnostic platforms.

Akribion gene editing platform can kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed, enabling healthcare professionals to quickly adapted the platform to target different cells, making it much faster to develop new treatments compared to traditional methods

AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. It develops alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation directly to tumors at the molecular level to allow healthcare providers to provide safe and effective treatment for multiple forms of cancer.

Oncomatryx is aimed at discovering new mechanisms and proteins in the peritumoral stroma, the cells, and the extracellular matrix that surround the tumour and facilitate its invasiveness, resistance to treatment, and metastasis, enabling doctors to diagnose, prognosis, and fight against tumour invasiveness.